Evidence-based use of recombinant FVIIa (NovoSeven®, NiaStase®) for the treatment of hemophilia with inhibitors in children and adolescents

Brahm Goldstein; Brian Geldziler; Jens Bjerre; Stephanie Seremetis

doi:10.1016/j.transci.2007.12.002

Evidence-based use of recombinant FVIIa (NovoSeven^®, NiaStase^®) for the treatment of hemophilia with inhibitors in children and adolescents

Brahm Goldstein
, Brian Geldziler
, Jens Bjerre
, Stephanie Seremetis

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Children and adolescents comprise a significant proportion of the hemophilia population, including those patients who have developed inhibitors to factor VIII or FIX. We examine the use of rFVIIa for the treatment of bleeding episodes and the prevention of bleeding in children and adolescents with hemophilia A and B with inhibitors, focusing on registry data and recent clinical trial results. Based on this review of the literature, we conclude that recombinant FVIIa is safe and effective for use in controlling bleeding in these patient populations.

Original language	English
Pages (from-to)	25-32
Number of pages	8
Journal	Transfusion and Apheresis Science
Volume	38
Issue number	1
DOIs	https://doi.org/10.1016/j.transci.2007.12.002
State	Published - Feb 2008
Externally published	Yes

Keywords

Bleeding disorder
Hemophilia
Inhibitors
NiaStase
NovoSeven
Recombinant FVIIa

Access to Document

10.1016/j.transci.2007.12.002

Cite this

@article{012941fd56e24146a3e41f587ce47e50,

title = "Evidence-based use of recombinant FVIIa (NovoSeven{\textregistered}, NiaStase{\textregistered}) for the treatment of hemophilia with inhibitors in children and adolescents",

abstract = "Children and adolescents comprise a significant proportion of the hemophilia population, including those patients who have developed inhibitors to factor VIII or FIX. We examine the use of rFVIIa for the treatment of bleeding episodes and the prevention of bleeding in children and adolescents with hemophilia A and B with inhibitors, focusing on registry data and recent clinical trial results. Based on this review of the literature, we conclude that recombinant FVIIa is safe and effective for use in controlling bleeding in these patient populations.",

keywords = "Bleeding disorder, Hemophilia, Inhibitors, NiaStase, NovoSeven, Recombinant FVIIa",

author = "Brahm Goldstein and Brian Geldziler and Jens Bjerre and Stephanie Seremetis",

year = "2008",

month = feb,

doi = "10.1016/j.transci.2007.12.002",

language = "English",

volume = "38",

pages = "25--32",

journal = "Transfusion and Apheresis Science",

issn = "1473-0502",

publisher = "Elsevier Ltd.",

number = "1",

}

TY - JOUR

T1 - Evidence-based use of recombinant FVIIa (NovoSeven®, NiaStase®) for the treatment of hemophilia with inhibitors in children and adolescents

AU - Goldstein, Brahm

AU - Geldziler, Brian

AU - Bjerre, Jens

AU - Seremetis, Stephanie

PY - 2008/2

Y1 - 2008/2

N2 - Children and adolescents comprise a significant proportion of the hemophilia population, including those patients who have developed inhibitors to factor VIII or FIX. We examine the use of rFVIIa for the treatment of bleeding episodes and the prevention of bleeding in children and adolescents with hemophilia A and B with inhibitors, focusing on registry data and recent clinical trial results. Based on this review of the literature, we conclude that recombinant FVIIa is safe and effective for use in controlling bleeding in these patient populations.

AB - Children and adolescents comprise a significant proportion of the hemophilia population, including those patients who have developed inhibitors to factor VIII or FIX. We examine the use of rFVIIa for the treatment of bleeding episodes and the prevention of bleeding in children and adolescents with hemophilia A and B with inhibitors, focusing on registry data and recent clinical trial results. Based on this review of the literature, we conclude that recombinant FVIIa is safe and effective for use in controlling bleeding in these patient populations.

KW - Bleeding disorder

KW - Hemophilia

KW - Inhibitors

KW - NiaStase

KW - NovoSeven

KW - Recombinant FVIIa

UR - https://www.scopus.com/pages/publications/40849102706

U2 - 10.1016/j.transci.2007.12.002

DO - 10.1016/j.transci.2007.12.002

M3 - Article

C2 - 18267372

AN - SCOPUS:40849102706

SN - 1473-0502

VL - 38

SP - 25

EP - 32

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

IS - 1